Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2000/055125
Kind Code:
A2
Abstract:
The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

Inventors:
BRYANT CLIFFORD M (US)
BUNIN BARRY A (US)
KRAYNACK ERICA A (US)
PATTERSON JOHN W (US)
Application Number:
PCT/US2000/006747
Publication Date:
September 21, 2000
Filing Date:
March 15, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
AXYS PHARM INC (US)
BRYANT CLIFFORD M (US)
BUNIN BARRY A (US)
KRAYNACK ERICA A (US)
PATTERSON JOHN W (US)
International Classes:
A61K31/275; A61K31/277; A61K31/341; A61K31/343; A61K31/36; A61K31/381; A61K31/395; A61K31/40; A61K31/404; A61K31/4045; A61K31/4164; A61K31/4166; A61K31/417; A61K31/426; A61K31/433; C07D295/12; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4436; A61K31/4439; A61K31/445; A61K31/4453; A61K31/4468; A61K31/454; A61K31/455; A61K31/465; A61K31/47; A61K31/495; A61K31/496; A61K31/505; A61K31/535; A61K31/5375; A61K31/54; A61K31/663; A61K45/00; A61P3/10; A61P5/14; A61P9/00; A61P9/10; A61P11/00; A61P11/06; A61P17/00; A61P17/02; A61P19/02; A61P19/10; A61P21/04; A61P25/00; A61P25/28; A61P27/02; A61P29/00; A61P33/00; A61P35/00; A61P37/00; A61P37/02; A61P37/08; A61P43/00; C07C253/30; C07C255/29; C07C255/60; C07C269/06; C07C271/22; C07C273/18; C07C275/24; C07C303/40; C07C311/06; C07C311/09; C07C315/04; C07C317/50; C07C319/20; C07C323/52; C07C323/60; C07C323/62; C07D207/09; C07D207/14; C07D207/16; C07D209/06; C07D209/08; C07D209/14; C07D209/22; C07D209/26; C07D209/42; C07D209/52; C07D211/58; C07D211/60; C07D211/62; C07D213/30; C07D213/34; C07D213/40; C07D213/56; C07D213/70; C07D213/71; C07D213/75; C07D213/81; C07D213/82; C07D215/54; C07D233/24; C07D233/26; C07D233/64; C07D233/90; C07D239/28; C07D239/36; C07D277/20; C07D277/28; C07D277/30; C07D277/42; C07D277/48; C07D277/56; C07D285/135; C07D295/14; C07D295/155; C07D295/18; C07D295/20; C07D295/215; C07D307/56; C07D307/68; C07D317/68; C07D333/20; C07D333/38; C07D333/68; C07D401/12; C07D405/06; C07D405/12; C07D409/04; C07D417/04; C07D417/12; (IPC1-7): C07C271/22; A61K31/275; A61P11/00; A61P17/00; A61P33/00; A61P35/00; A61P37/00; A61P25/00; A61P29/00; C07D209/26; C07C323/60; C07D233/26; C07D233/90; C07D277/56; C07C275/24
Domestic Patent References:
WO1998001133A11998-01-15
WO1999024460A21999-05-20
Other References:
HANZLIK, ROBERT P. ET AL: "Reversible covalent binding of peptide nitriles to papain" BIOCHIM. BIOPHYS. ACTA, vol. 1035, no. 1, 1990, pages 62-70, XP000929836
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOSHIDA, HIROSHI ET AL: "Preparation of N-(2-chloroisonicotinoyl) amino acid amides as agrochemical microbicides" retrieved from STN Database accession no. 110:213341 XP002144654 & JP 63 301868 A (NIPPON KAYAKU CO., LTD., JAPAN) 8 December 1988 (1988-12-08)
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SUZUE, SEIGO ET AL: "Hepatic agents. I. Synthesis of aminoacyl (and hydroxyacyl)aminoacetonitriles" retrieved from STN Database accession no. 70:11969 XP002144655 & CHEM. PHARM. BULL. (TOKYO) (1968), 16(8), 1417-32,
Attorney, Agent or Firm:
Kezer, William B. (CA, US)
Download PDF:
Claims:
WE CLAIM:
1. A compound of Formula (I): inwhich: R'is a group of Formula (a) or (b): wherein: X'and X2 independently areC (O)orCH2S (O) 2; R5 and R6 are hydrogen or (Cl 6) alkyl; R7 and R8 are hydrogen or (Chalky 1 or as defined below; R9 and R10 independently are (i) (C16)alkyl optionally substituted with cyano, halo or nitro or (ii) a group selected from X3NR12R13, X3NR12C(O)OR13, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3C(O)OR12,X3P(O)(OR12)OR12,X3S(O)2NR12R12, X3S(O)R13,X3S(O)2R13,X3C(O)R13,X3OP(O)(OR12)OR12,X3NR12C(O)R13, X3OC(O)R14,X3NR15C(O)R14,X3NR15C(O)OR14,X3C(O)R14,X3C(O)OR14, X3NR15C(O)NR14R15,X3C(O)NR14R15,X3S(O)2NR14R15, X4S(O)R14,X4S(O)2R14,X4OR14,orX3NR15C(NR15)NR14R15,X4SR14 X3is(C16)alkylene,X4isabondor(C16)alkylene,R12ateachX4NR14R15,wherein occurrence independently is hydrogen, (C16)alkyl or halosubstituted (Cl 3) alkyl, R13 is halosubstituted(C13)alkyl,R14is(C313)cycloalkyl(C06)alkyl,or hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, (C912) polycycloaryl (CO6) alkyl or hetero (C8 l2) polycycloaryl (C06) alkyl and R15 is hydrogen or (C16) alkyl, and wherein within Rl4 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group R16,X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,from X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4C(O)R16,X4C(O)OR16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4NR17C(NR17)NR16R17, wherein X4 is a bond or (C16)alkylene, R16 is hydrogen or (C16) alkyl and R17 is (C312) cycloalkyl (CO6) alkyl, hetero (C3 l2) cycloalkyl (C06) alkyl, (C612) aryl (CO6) alkyl, hetero (C512) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl or hetero (C8 l2) polycycloaryl (C06) alkyl, or (iii) a group selected from (C612)aryl(C06)alkyl,(C312)cycloalkyl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl, hetero (C512) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl and hetero (C8 l2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group R16,X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,from X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4C(O)R16,X4C(O)OR16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4,R16andR17areasdefinedabove;whereinX4NR17C(NR17)NR16R17,wherein within R9 and/or R10 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16) alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X4NR12R12, X4NR12C(O)OR12, X4OR12,X4SR12,X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12, X4S(O)2NR12R12,X4P(O)(OR4)OR12,X4C(O)OR12,X4C(O)NR12R12, X4NR12C(O)R13,X4S(O)R13,X4S(O)2R13X4OP(O)(OR12)OR12,X4OC(O)R13, andX4C (o) Rl3, wherein X4, R12 and R13 are as defined above, or R9 taken together with R7 and/or R10 taken together with R8 form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene; and X5X6R18,whereinX5isC(O),C(O)C(O)orS(O)2,X6isaR11is bond,OorNR'9, wherein R19 is hydrogen or (Calkyi, and R18 is (i) (C110) alkyl optionally substituted by cyano, halo, nitro, NR12R12, NR12C(NR12)NR12R12,OR12,SR12,NR12C(O)OR12,NR12C(O)NR12R12, S(O)2NR12R12,P(O)(OR12)OR12,C(O)OR12,C(O)NR12R12, OPCOXOROR12,NRCCCQR13,S(0)R13,SR13,C(0)R13,OR20,SR20, C(O)R20,C(O)OR20,C(O)NR20R21,NR20R21,S(O)R20,S(O)2R20, orNR21C(NR21)NR20R21,NR21C(O)R20,NR21C(O)OR20,NR21C(O)NR20R21 wherein R12 and R13 are as defined above, R20 is (C3 l2) cycloalkyl (C06) alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, hetero(C812)bicycloaryl(C06)alkylandR21ateach(C912)bicycloaryl(C06)alkylor occurrence independently is hydrogen or (C16)alkyl, or hetero(C312)cycloalkyl(C06)alkyl,(ii)(C312)cycloalkyl(C06)alkyl, (C912)bicycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512aryl(C06)alkyl, hetero (C812) bicycloaryl (C06) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X4S(O)R22,X4S(O)2R22,X4C(O)R22,X4C(O)OR22,X4OR22,X4SR22, X4NR23C(O)R22,X4NR23C(O)OR22,X4C(O)NR22R23,X4NR22R23, X4NR23C(O)NR22R23 or X4NR23C(NR23)NR22R23, wherein X4 is as defined above, R22 is (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl and R23 at each occurrence independently is hydrogen or (Cl6) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16)alkylidene, cyano, halo, halosubstituted (Calkyi, X4NR12C(O)OR12,X4NR12C(O)NR12R12,nitro,X4NR12R12, X4SR12,X4C(O)OR12,X4C(O)NR12R12,X4NR12C(NR12)NR12R12,X4OR12, X4OP(O)(OR3)OR12,X4OC(O)R13,X4S(O)2NR12R12,X4P(O)(OR3)OR12, X4S(O)2R13andX4C(O)R13,whereinX4,R12andX4NR12C(O)R13,X4S(O)R13, R13 are as defined above; R2 is hydrogen or (C16)alkyl or as defined below; R3 is hydrogen, (C16) alkyl or as defined below; and R4 is (i) hydrogen or (CI 6) alkyl, wherein said alkyl is optionally substituted with cyano, halo, NR12C(O)OR12,NR12C(O)NR12R12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, (OXOROR12,OPXOROR12,NR'OR13,S(0)R13,SQR13,C(0)R13, S(O)R14,S(O)2R14,C(O)R14,C(O)OR14,OC(O)R14,NR14R15,OR14,SR14, C(O)NR14R15,S(O)2NR14R15,NR15C(O)NR14R15orNR15C(O)R14,NR15C(O)OR14, NR15C(NR15)NR14R15, wherein R14andR15areasdefinedabove,or(ii)agroupR13, selected from (C312) cycloalkyl (CO6) alkyl, hetero (C3 l2) cycloalkyl (C06) alkyl, (C612)aryl(C06) alkyl, hetero (C5 l2) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl and hetero (C8 l2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,X4C(O)R16,R16, X4NR16R17,X4NR17C(O)R16,X4NR17C(O)OR16,X4C(O)OR16,X4OC(O)R16, X4NR17C(O)NR16R17orX4NR17C(NR17)NR16R17,X4C(O)NR16R17,X4S(O)2NR16R17, wherein X4, R16 and R17are as defined above; wherein within R9 and/or R10 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (Cl 6) alkylidene, cyano, halo, halosubstituted (Cl 4) alkyl, nitro, X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12,X4NR12R12,X4NR12C(O)OR12, X4C(O)OR12,X4C(O)NR12R12,X4S(O)2NR12R12,X4OR12,X4SR12, <BR> <BR> (OXOROR12,X40P(OXOR3)OR12,XCR13,X4NR12C(0)R13,X4S(0)R13,<BR> <BR> X4S (O)2 2Rl3 andX4C (O) R13, wherein X4, R12 and R13 are as defined above, or R4 and R2 taken together form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene, or R4 and R3 together with the carbon atom to which both R4 and R3 are attached form (C38) cycloalkylene or (C38) heterocycloalkylene; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
2. The compound of Claim 1 in which: R'is a group of Formula (a) wherein within Formula (a): X'isC (O) ; hydrogenor(C16)alkyl;R5is R7 is hydrogen or methyl; R9 is (i) (C16) alkyl optionally substituted withOR,SR,S (O) R SCCQaR14,C(0)R14,C(0)OR14,OC(0)R14,NRR15,NRCR14,<BR> NRCCOpR14,CCCONRR15,S(0)2NR14R15,NRCNRR15or NR15C(NR15)NR14R15, wherein R14 is (C3_lo) cycloalkyl (Co6) alkyl, hetero (C3 l0) cycloalkyl (CO 6) alkyl, (C610) aryl (C06) alkyl, hetero (C5 l0) aryl (C06) alkyl, (C910)polycycloaryl(C06) alkyl or hetero (C8 l0) polycycloaryl (C06) alkyl and R15 is hydrogen or (Cl 6) alkyl, and wherein within R14 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3C(0)R16,X3C(0)OR16,X30C(0)R16,XRR17,X3NR17C(0)R16, X3S(O)2NR16R17,X3NR17C(O)NR16R17orX3NR17C(O)OR16,X3C(O)NR16R17, X3isabondor(C16)alkylene,R16ishydrogenorX3NR17C(NR17)NR16R17,wherein (C16)alkyl and (C310)cycloalkyl(C06)alkyl,hetero(C310)cycloalkyl(C06)alkyl,is (C610)aryl(C06) alkyl, hetero (C510) aryl (C06) alkyl, (C9 l0) polycycloaryl (Co6) alkyl or hetero (Cg. io) polycycloaryl (C06) alkyl, or (ii) a group selected from (C610)aryl(C06)alkyl,(C310)cycloalkyl(C06)alkyl,hetero(C310)cycloalkyl(C06)alkyl, andhetero(C510)aryl(C06)alkyl,(C910)polycycloaryl(C06)alkyl hetero (C8 l0) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3OC(O)R16,X3NR16R17,X3NR17C(O)R16,X3C(O)R16,X3C(O)OR16, X3NR17C(O)OR16, X3C(O)NR16R17, X3S(O)2NR16R17, X3NR17C(O)NR16R17 or X3,R16andR17areasdefinedabove;whereinX3NR17C(NR17)NR16R17,wherein within R9 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16)alkylidene, cyano, halo, halosubstituted (Cl 4) alkyl, nitro, X3NR12R12, X3NR12C(O)OR12, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, X3NR12C(O)R13,X3S(O)R13,X3S(O)2R13X3OP(O)(OR3)OR12,X3OC(O)R13, andandX3C(O)R13, wherein X3is as defined above, R12at each occurrence independently is hydrogen, (C16) alkyl or halosubstituted (C13) alkyl and R13 is halosubstituted(C13)alkyl;and(C16)alkylor R11 is X4X5R18, wherein X4 isC (O)orS (O) 2, Xs is a bond,Oor NRl9, wherein R'9 is hydrogen or (Calkyi, and R18 is (i) (C110) alkyl or hetero(C312)cycloalkyl(C06)alkyl,(ii)(C312)cycloalkyl(C06)alkyl, (C612)aryl(C06) alkyl or hetero (C512) aryl (CO6) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X9C(O)OR24,X9C(O)NR24R25,X9NR24R25,X9OR24,X9C(O)R24, X9NR25C (O) R24, X9NR25C(O)OR24, X9NR25C(O)NR24R25 or X9NR25C (NR25) NR24R25, wherein X9 is a bond or (Cl 6) alkylene, R24 is (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl and R25 is hydrogen or (C16) alkyl, wherein within R"any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (Cl 6) alkyl, halo, halosubstituted (C14) alkyl, C(O)OR12andX3NR12C(O)OR12,whereinX3isabondorOR12,X3SR12, (C16)alkylene and R14 is hydrogen or (C16)alkyl ; hydrogen;R2is R3 is hydrogen or (Cl 4) alkyl or taken with R4 together with the carbon atom to which both R3 and R4 are attached forms (C38) cycloalkylene; and R4 is hydrogen or as defined above; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
3. The compound of Claim 2 in which: R'is a group of Formula (a) wherein within Formula (a): R and R7 both are hydrogen; R9 is (i) (Cl 6) alkyl optionally substituted with OR14 or SR14, wherein R14 is (C36) cycloalkyl (CO6) alkyl, phenyl (CO6) alkyl, biphenylyl (CO6) alkyl or hetero (C56) aryl (C06) alkyl, or (ii) a group selected from (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl, biphenylyl (C06) alkyl or hetero (C5 l0) aryl (C06) alkyl; wherein within R9 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16)alkylidene, cyano, halo, halosubstituted X3NR12R12,X3NR12C(O)OR12,nitro, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, X3OC(O)R13,X3NR12C(O)R13,X3OP(O)(OR3)OR12,X3OC(O)R13, X3S (O) R13, X3S(O)2R13 and X3C(O)R13, wherein X3 is a bond or (C16)alkylene, R12 at each occurrence independently is hydrogen, (C13) alkyl or halosubstituted (C13) alkyl and R13 is (C13)alkyl or halosubstituted (C13) alkyl; and R"isXR18, wherein X4 is C(O), X5 is a bond and R18 is (i) hetero(C312)cycloalkyl(C06)alkyl, (C612)aryl(C06) alkyl or hetero (C5 l2) aryl (C06) alkyl or (ii) phenyl (C06) alkyl or hetero (Cs 6) aryl (C06) alkyl, wherein said phenyl or heteroaryl is substituted by X9C(O)OR24,X9C(O)NR24R25,X9NR24R25,X9OR24,X9C(O)R24, X9NR25C(O)NR24R25X9NR25C(O)R24,X9NR25C(O)OR24, or X9NR25C (NR25) NR24R25, wherein X9 is a bond or (C16)alkylene, R24 is phenyl (Co6) alkyl or hetero (C56) aryl (C06) alkyl and R25 is hydrogen or (Cl 6) alkyl, wherein within R11 any aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (Cl 6) alkyl, halo, halosubstituted X3SR12,C(O)OR12andX3NR12C(O)OR12whereinX3isa(C14)alkyl,OR12, bond or (Cl6) alkylene and R12 is hydrogen or (C16) alkyl ; and R3 and R4 are both hydrogen; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
4. The compound of Claim 3 in which within Formula (a) R9 is cyclohexylmethyl, wherein said cyclohexyl may be substituted by 1 to 5 radicals independently selected from (C14) alkyl, (Cl6) alkylidene orX3OC (o) R'3, or phenylmethylsulfanylmethyl or phenylsulfanylethyl, wherein said phenyl may be substituted by 1 to 5 radicals independently selected from (Cl 4) alkyl, cyano, halo, halosubstituted (C14)alkyl, nitro, OR12, SR12 and C (O) OR12, wherein R12 is hydrogen, (C13)alkyl or halosubstituted (C1_3) alkyl and R13 is (C16) alkyl or halosubstituted (Cl 3) alkyl; and R11 is benzoyl, furylcarbonyl, phenyloxybenzoyl, pyridylthienylcarbonyl, benzoylbenzoyl, thienylcarbonyl, morpholinylcarbonyl, phenyluriedobenzoyl, cyclohexenylcarbonyl or piperazinylcarbonyl, wherein within R11 any aromatic ring system present may be substituted further by 1 to 2 substituents independently selected from (Cl 6) alkyl, tertbutoxycarbonylamino, tertbutoxycarbonylaminomethyl, bromo, chloro, ethoxy, fluoro, hydroxy, methoxy and methylsulfanyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
5. The compound of Claim 4 in which within Formula (a), R9 is a group having the following formula: in which q is 0 to 5 and R26 at each occurrence is independently selected from (C1_4) alkyl, cyano, halo, halosubstituted (Cl 4) alkyl, nitro,ORl2,SR'2 andC (O) OR'2, wherein R12 is hydrogen, (C13) alkyl or halosubstituted (Cl_3) alkyl and R'3 is (C, 6) alkyl or halosubstituted (CI3) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
6. The compound of Claim 3 in which within Formula (a), R9 is benzylsulfanylmethyl, 2bromobenzylsulfanylmethyl, 2chlorobenzylsulfanyl, 2 (2chlorophenylsulfanyl) ethyl, cyclohexyl, 4ethylidenecyclohexyl, 2iodobenzylsulfanylmethyl, 2methylbenzylsulfanylmethyl, 3methyl 3trifluorocarbonyloxycyclohexylmethyl, 4methylenecyclohexylmethyl or 2nitrobenzylsulfanylmethyl and R"is 4tertbutoxycarbonylaminobenzoyl, 3tertbutoxycarbonylaminomethylbenzoyl, 2 (3,5dimethoxyphenyl) thiazol4ylcarbonyl, fur3ylcarbonyl, 4methoxybenzoyl, 3methylbenzoyl, 3phenoxybenzoyl, 5pyrid2ylthien 2ylcarbonyl, 3benzoylbenzoyl, 4methylbenzoyl, thien2ylcarbonyl, morpholin4 ylcarbonyl, 5bromothien2ylcarbonyl, 5chlorothien2ylcarbonyl, 5methylthien2ylcarbonyl, 2 (2chloro6methylphenyl) ureidobenzoyl, cyclohexyl1en1 ylcarbonyl, 3ethoxybenzoyl, 3fluorobenzoyl, 4fluorobenzoyl and piperidin1ylcarbonyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
7. The compound of Claim 6 selected from a group consisting of: N (2benzylsulfanyl1Rcyanomethylcarbamoylethyl)4hydroxybenzamide; N[2(2bromobenzylsulfanyl)lRcyanomethylcarbamoylethyl][2(2bromobenzylsulfanyl)lRcyanomethylcarbamoylethyl] benzamide; N[lRcyanomethylcarbamoyl2(2iodobenzylsulfanyl)[lRcyanomethylcarbamoyl2(2iodobenzylsulfanyl) ethyl] benzamide; N[lRcyanomethylcarbamoyl2(2cyanobenzylsulfanyl) ethyl] morpholine 4carboxamide; N [3 (2chlorophenylsulfanyl)lRcyanomethylcarbamoylpropyl] benzamide; N [lRcyanomethylcarbamoyl2 (2nitrobenzylsulfanyl) ethyl] morpholine 4carboxamide N [IRcyanomethylcarbamoyl2 (2methylbenzylsulfanyl) ethyl] morpholine 4carboxamide; and N [lRcyanomethylcarbamoyl2 (2methylbenzylsulfanyl) ethyl] benzamide; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
8. A pharmaceutical composition comprising a compound of Claim 1, or a Noxide derivative, prodrug derivative, individual isomer, mixture of isomers, or a pharmaceutically acceptable salt thereof in admixture with one or more suitable excipients.
9. A method of treating a disease in an animal in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease, which method comprises administering to the animal a therapeutically effective amount of compound of Claim 1; or a Noxide derivative, prodrug derivative, individual isomer or mixture of isomers or a pharmaceutically acceptable salt thereof.
10. The method of Claim 9 in which the cysteine protease is cathepsin S.
11. The method of Claim 10 in which the disease is an autoimmune disorder, allergic disorder, allogeneic immune response, a disorder involving excessive elastolysis, cardiovascular disorders or a disorder involving fibril formation.
12. The method of Claim 11 in which the disorder is selected from juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves'disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis, Hashimoto's thyroiditis, asthma, organ transplant or tissue graft rejections, chronic obstructive pulmonary disease, bronchiolitis, excessive airway elastolysis in asthma and bronchitis, pneumonities, plaque rupture, atheroma and systemic amyloidosis.
13. A compound according to claim 1 in which R1 is a group of formula (a) wherein X1 isCH2S (O) 2; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
14. A compound according to any one of claims 13 and 13 in which is a group of formula (a) wherein R9is a group having the formula in which q is 0 to 5 and R26 at each occurrence is independently selected from (Cl 4) alkyl, cyano, halo, halosubstituted (C, 4) alkyl, nitro,oR'2,SR'2 andC (O) OR'2, wherein R12 is hydrogen, (C13) alkyl or halosubstituted (C, 3) alkyl and R13 is (CI6) alkyl or halosubstituted (CI3) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
15. A compound according to claim 14 in which at least one R26 group is attached at the benzene ring 2position; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
16. A compound according to claim 15 in which the benzene ring is substituted by one R26 group at the 2position wherein R26 is selected from at each occurrence is independently selected from (C, 4) alkyl, cyano, halo, halosubstituted (C14) alkyl, nitro, OR12, SR12 and C(O)OR12, wherein R12 is hydrogen, (C13) alkyl or halosubstituted (Ci3) alkyl and R13 is (C1_6) alkyl or halosubstituted (C_3) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
17. A compound according to claim 16 in which R26 is difluoromethoxy; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
18. A compound of Formula (II): wherein: R2 is hydrogen or (Cl 6) alkyl or as defined below; R3 is hydrogen, (C16)alkyl or as defined below; R4 is (i) hydrogen or (C16)alkyl, wherein said alkyl optionally is substituted with cyano, halo, NR12C(O)OR12,NR12C(O)NR12NR12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, <BR> <BR> (OXOROR12,OPXOROR12,NR'COR13,S(0)R13,SR13,C(0)R13,<BR> <BR> OR14,SR14,S(0)R14,S(0)2R14,C(0)R14,C(0)OR14,OC(0)R14,NRR15, C(O)NR14R15,S(O)2NR14R15,NR15C(O)NR14R15orNR15C(O)R14,NR15C(O)OR14, NR15C(NR15)NR14R15, wherein R12at each occurrence independently is hydrogen, halosubstituted(C13)alkyl,R13is(C16)alkylorhalosubstituted(C13)alkyl,R14(C16)alkylor is (C312)cycloalkyl(C06) alkyl, hetero (C3 l2) cycloalkyl (CO 6) alkyl, (C6 l2) aryl (Co6) alkyl, hetero (C512) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl or hetero (C812) polycycloaryl (CO6) alkyl and R15 is hydrogen or (Cl 6) alkyl, and wherein within R14 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected from R16, X4OR16, X4SR16, X4S(O)R16, X4C(O)OR16,X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4S(O)2R16,X4C(O)R16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4isabondor(C16)alkylene,R16ishydrogenorX4NR17C(NR17)NR16R17,wherein (Cl 6) alkyl and R17 is (C312) cycloalkyl (C06) alkyl, hetero (C3 l2) cycloalkyl (C06) alkyl, (C912)polycycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C8 l2) polycycloaryl (C06) alkyl, or (ii) a group selected from (C612)aryl(C06)alkyl,(C312)cycloalkyl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl, andhetero(C512)aryl(C06)alkyl,(C912)polycycloaryl(C06)alkyl hetero (C812) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,X4C(O)R16,R16, X4NR16R17,X4NR17C(O)R16,X4NR17C(O)OR16,X4C(O)OR16,X4OC(O)R16, X4NR17C(O)NR16R17orX4NR17C(NR17)NR16R17,X4C(O)NR16R17,X4S(O)2NR16R17, wherein X4, R16 and R17 are as defined above; wherein within R4 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from cyano,halo,halosubstituted(C14)alkyl,nitro,X4NR12R12,(C16)alkyl,(C16)alkylidene, X4NR12C(NR12)NR12R12,X4OR12,X4SR12,X4NR12C(O)OR12,X4NR12C(O)NR12R12, X4S(O)2NR12R12,X4P(O)(OR3)OR12,X4C(O)OR12,X4C(O)NR12R12, X40P(0)(OR3)OR12,XCXOR13,XRCR13,XCOR13,X4S(0)2R13and X4C (O) Rl3, wherein X4, R12 and R13 are as defined above, or R4 and R2 taken together form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene, or R4 and R3 together with the carbon atom to which both R4 and R3 are attached form (C38) cycloalkylene or (C38) heterocycloalkylene; hydrogenor(C16)alkyl;R5is R7 is hydrogen or (Cl 6) alkyl; R9 is X4OR14,X4SR14,hetero(C512)aryl(C06)alkyl, X4S(O)R14,X4NR14R15,whereinX4,R14andR15areasdefinedaboveandor wherein within R9 said aryl or heteroaryl ring optionally is substituted by 1 to 5 radicals independently selected from (Cl 6) alkyl, cyano, halo, halosubstituted (C14) alkyl, nitro, X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12,X4NR12R12,X4NR12C(O)OR12, X4C(O)R12,X4C(O)OR12,X4C(O)NR12R12,X4S(O)2NR12R12,X4OR12,X4SR12, X4OC(O)R13,X4NR12C(O)R13,X4S(O)R13,X4P(O)(OR3)OR12,X4OP(O)(OR3)OR12, X4S (O) 2R13, wherein X4, R12 and R13 are as defined above; and R11 isXR18, wherein X5 isC (O),C (O) C (O)orS (O) 2, x6 is a bond,O orNR'9, wherein R19 is hydrogen or (C16)alkyl, and R18 is (i) (Cl l0) alkyl optionally substituted by cyano, halo, nitro, NR12R12, NR12C(O)OR12, NR12C(O)NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, PCOXOR'OR12,OPCOXOR'OR12,NRCR13,S(0)R13,S(0)2R13,C(0)R13, S(O)R20,S(O)2R20,C(O)R20,C(O)OR20,C(O)NR20R21,NR20R21,OR20,SR20, orNR21C(NR21)NR20R21,whereinNR21C(O)R20,NR21C(O)OR20,NR21C(O)NR20R21 R12 and R13 are as defined above, R20 is (C3 l2) cycloalkyl (C06) alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, (C912)bicycloaryl(C06) alkyl or hetero (C8 l2) bicycloaryl (CO6) alkyl and R21 at each occurrence independently is hydrogen or (Calkyi, or (ii) (C3 l2) cycloalkyl (C06) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C6, 2) aryl (CO 6) alkyl, hetero (C5 12) aryl (C06) alkyl, (C912) bicycloaryl (CO6) alkyl or hetero (C812) bicycloaryl (CO6) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (CO6) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is X4OR22,X4SR22,X4S(O)R22,X4S(O)2R22,X4C(O)R22,X4C(O)OR22,substitutedby X4NR23C(O)R22,X4NR23C(O)OR23,X4C(O)NR22R23,X4NR22R23, X4NR23C(NR23)NR22R23,whereinX4isasdefinedabove,R22isX4NR23C(O)NR22R23or (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl and R23 at each occurrence independently is hydrogen or (C16) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16) alkylidene, cyano, halo, halosubstituted X4NR12R12,X4NR12C(O)OR12,nitro, X4OR12,X4SR12,X4C(O)OR12,X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12, X4P(O)(OR3)OR12,X4OP(O)(OR3)OR12,X4C(O)NR12R12,X4S(O)2NR12R12, X4OC(O)R13,X4S(O)2R13andX4C(O)R13,whereinX4,X4S(O)R13, R12 and R13 are as defined above; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
19. The compound of Claim 18 in which: hydrogen;R2is R3 is hydrogen, methyl or taken with R4 together with the carbon atom to which both R3 and R4 are attached forms (C38) cycloalkylene; R4 is hydrogen, methyl or as defined above; R 5is hydrogen or (C16) alkyl; R'is hydrogen or methyl; R9 represents (C6 l2) aryl (C06) alkyl, hetero (C512) aryl (Co6) alkyl, X4OR14, X4SR14, X4S(O)R14 or X4NR14R15, wherein X4 is a bond or (C16)alkylene, R14 is (C6 l2) aryl (C06) alkyl or hetero (C512) aryl (CO6) alkyl and R15 is hydrogen or (Calkyi, and wherein within R9 said aryl or heteroaryl ring optionally is substituted by 1 to 5 radicals independently selected from (C16)alkyl, cyano, halo, halosubstituted (Cl 4) alkyl, nitro, X4C(O)R12,X4SR12,whereinX4isabondor(C16)alkylene,R12atX4NR12R12,X4OR12, each occurrence independently is hydrogen, (C16)alkyl or halosubstituted (C13) alkyl, and R13 is (C16) alkyl or halosubstituted (C13)alkyl ; and R11 is X4X5R18, wherein X4 isC (O)orS (O) 2, X5 is a bond,OorNRl9, wherein R19 is hydrogen or (C16)alkyl, and R18 is (i) (Cl l0) alkyl or (ii) (C3 l2) cycloalkyl (C06) alkyl, hetero (C3 l2) cycloalkyl (C06) alkyl, (C612) aryl (CO6) alkyl or hetero (C512) aryl (CO6) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X9OR24,X9C(O)R24, X9NR24R25,X9NR25C(O)R24,X9NR25C(O)OR24,X9C(O)OR24,X9C(O)NR24R25, X9NR25C (O) NR24R25 or X9NR25C(NR25)NR24R25, wherein X9 is a bond or (C16)alkylene, R24 is phenyl(C06)alkylorhetero(C36)cycloalkyl(C06)alkyl, hetero (C56) aryl (C06) alkyl and R25 is hydrogen or (C16) alkyl, wherein within R"any alicyclic or aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from halosubstituted(C14)alkyl,OR12,X3SR12,halo, C (O) OR12 and X3NR12C(O)OR12, wherein X3 is a bond or (Cl 6) alkylene and R14 is hydrogen or (C16) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
20. The comound of Claim 19 in which: R3, R4, R5 and R7 each are hydrogen; R9 represents benzyl, benzyloxymethyl, benzylsulfanylethyl, benzylsulfanylmethyl, benzylsulfinylmethyl, indolylmethyl, naphthylmethyl, phenethyl, phenoxyethyl, phenylamino, pyridylmethyl, pyridylsulfanylethyl, phenylsulfanylethyl, thiazolyl or thienyl, wherein within R9 the aromatic ring may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, cyano, halo, halosubstituted (C14)alkyl, nitro, X4NR12R12, X4OR12, whereinX4isabondor(C16)alkylene,R12ateachoccurrenceX4C(O)R12,X4SR12, independently is hydrogen, halosubstituted(C13)alkyl,andR13is(C16)alkyloror halosubstituted (C13) alkyl; and R11 is X4X5R18, wherein X4 iSC (O), X5 iS a bond and R18 is (i) (C3 l2) cycloalkyl (C06) alkyl, hetero (C3 l2) cycloalkyl (C06) alkyl, (C612) aryl (CO6) alkyl or hetero (C512) aryl (CO6) alkyl or (ii) phenyl (CO6) alkyl or hetero (C56) aryl (C06) alkyl, wherein said phenyl or heteroaryl is substituted X9C(O)R24,X9C(O)OR24,X9OR24, X9C(O)NR24R25,X9NR25C(O)OR24,X9NR25C(O)R24, _X9NR25C (O) NR24R25 orX9NR25C (NR25)NR24R25, wherein X9 is a bond or (C16)alkylene, R24 is phenyl (Co6) alkyl or hetero (C56) aryl (C06) alkyl and R25 is hydrogen or (C16) alkyl, wherein within R11 any aromatic ring system present may be substituted further by 1 to 5 substituents independently selected from (C16)alkyl, halo, halosubstituted (C14)alkyl, OR12, X3SR12, C(O)OR12 and X3NR12C(O)OR12 wherein X3 is a bond or (C16) alkylene and R12 is hydrogen or (Cl 6) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
21. The compound of Claim 20 in which R9 is a group having the following formula: in which q is 0 to 5 and R26 at each occurrence is independently selected from (C14) alkyl, cyano, halo, halosubstituted (Cl 4) alkyl, nitro,ORl2,SRl2 andC (O) ORl2, wherein R12 is hydrogen, (Cl 3) alkyl or halosubstituted (Cl 3) alkyl and Rl3 is (Cl 6) alkyl or halosubstituted (Cl 3) alkyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
22. The compound of Claim 20 in which R9 is 4aminobenzyl, benzyl, benzyloxymethyl, 2benzylsulfanylethyl, benzylsulfanylmethyl, 2bromobenzylsulfanylmethyl, 4tertbutylbenzylsulfanylmethyl, 2chlorobenzyl, 4chlorobenzyl, 2chlorobenzylsulfanylmethyl, 4chlorobenzylsulfanylmethyl, 2 (2chlorophenylsulfanyl) ethyl, 4cyanobenzyl, 3,4dichlorobenzylsulfanylmethyl, 1,6dichlorobenzyl, 3,5dimethylbenzylsulfanylmethyl, 2fluorobenzyl, 4fluorobenzyl, 2fluorobenzylsulfanylmethyl, 1formylindol3ylmethyl, indol3ylmethyl, 2iodobenzylsulfanylmethyl, 2methylbenzylsulfanylmethyl, 3methylbenzylsulfanylmethyl, 3methylbenzylsulfanylmethyl, 4methylbenzylsulfanylmethyl, 2 (2methylphenylsulfanyl) ethyl, 4methoxybenzyl, 4methoxybenzylsulfanylmethyl, 4methoxybenzylsulfinylmethyl, naphth2ylmethyl, naphth2ylmethylsulfanylmethyl, 3nitrobenzyl, 1nitrobenzylsulfanylmethyl, 2nitrobenzylsulfanylmethyl, 3nitrobenzylsulfanylmethyl, 4nitrobenzylsulfanylmethyl, 4nitrobenzyl, pentafluorobenzylsulfanylmethyl, phenylamino, phenethyl, phenethyloxy, 2phenoxyethyl, 2phenoxyethyl 2phenylsulfanylethyl, pyrid4ylmethyl, pyrid2ylmethylsulfanylmethyl, pyrid3ylmethylsulfanylmethyl, pyrid4ylmethylsulfanylmethyl, 2pyrid2ylsulfanylethyl, 2pyrid4ylsulfanylethyl, thiazol5yl, thien2ylmethyl, 4trifluoromethylbenzylsulfanylmethyl, 3trifluoromethylbenzylsulfanylmethyl, 3trifluoromethoxybenzylsulfanylmethyl, 4trifluoromethoxybenzylsulfanylmethyl or 4trifluorosulfanylbenzylsulfanylmethyl; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
23. The compound of Claim 22 which is selected a group from consisting of: N (2benzylsulfanyl1Rcyanomethylcarbamoylethyl)4hydroxybenzamide; N [2 (2bromobenzylsulfanyl)1Rcyanomethylcarbamoylethyl] benzamide ; N[lRcyanomethylcarbamoyl2(2iodobenzylsulfanyl)[lRcyanomethylcarbamoyl2(2iodobenzylsulfanyl) ethyl] benzamide; N [1 Rcyanomethylcarbamoyl2 (2cyanobenzylsulfanyl) ethyl] morpholine 4carboxamide; N [3 (2chlorophenyisulfanyl)IReyanomethylcarbamoylpropyl] benzamide; N[lRcyanomethylcarbamoyl2(2nitrobenzylsulfanyl)[lRcyanomethylcarbamoyl2(2nitrobenzylsulfanyl) ethyl] morpholine <BR> 4carboxamide<BR> N[lRcyanomethylcarbamoyl2(2methylbenzylsulfanyl) ethyl] morpholine 4carboxamide; and N[lRcyanomethylcarbamoyl2(2methylbenzylsulfanyl) ethyl] benzamide [lRcyanomethylcarbamoyl2(2methylbenzylsulfanyl) ethyl] benzamide and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof.
24. A compound according to any preceding claim for use in therapy.
25. A compound or pharmaceutical composition according to any preceding claim for use in treating a disease in an animal in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease.
26. A compound or pharmaceutical composition for use according to claim 25 in which the cysteine protease is cathepsin S.
27. A compound or pharmaceutical composition for use according to claim 26 to treat asthma.
28. Use of a compound according to any preceding claim for the manufacture of a medicament for the treatment of a disease in an animal in which cysteine protease activity contributes to the pathology and/or symptomatology of the disease.
29. Use according to claim 28 for the treatment of a disease in an animal in which cathepsin S activity contributes to the pathology and/or symptomatology of the disease.
30. Use according to claim 29 for the treatment of asthma.
31. A compound or pharmaceutical composition according to any preceding claim and an antiinflammatory agent as a combined preparation for simultaneous, separate or sequential use in the treatment of asthma.
32. A compound, pharmaceutical composition or use thereof substantially as herein described with reference to the Examples.
33. A method of treating a disease in an animal in which cathepsin S activity contributes to the pathology and/or symptomatology of the disease, which method comprising administering to the animal a therapeutically effective amount of a compound of Formula (I): in which: R'is a group of Formula (a) or (b): wherein: X'and X2 independently areC (O)orCH2S (O) 2; R5 and R6 are hydrogen or (C16)alkyl ; R7 and R8 are hydrogen or (C16)alkyl or as defined below; R9 and R10 independently are (i) (C16)alkyl optionally substituted with cyano, halo or nitro or (ii) a group selected from X3NR12R12, X3NR12C(O)OR12, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR12)OR12,X3C(O)OR12,X3C(O)OR12R12, XOXOROR12,NRCR13,XCR13,XCR13,XCQR13, X3OC(O)R14,X3NR15C(O)R14,X3NR15C(O)OR14,X3C(O)R14,X3C(O)OR14, X3NR15C(O)NR14R15,X3C(O)NR14R15,X3S(O)2NR14R15, X4S(O)R14,X4S(O)2R14,X4OR14,orX3NR15C(NR15)NR14R15,X4SR14 X3is(C16)alkylene,X4isabondor(C16)alkylene,R12ateachX4NR14R15,wherein occurrence independently is hydrogen, halosubstituted(C13)alkyl,R13or is (Cl 6) alkyl or halosubstituted (C13) alkyl, R14 is (C3 l2) cycloalkyl (CO6) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C6 l2) aryl (CO 6) alkyl, hetero (C512)aryl(C06) alkyl, (C912)polycycloaryl(C06) alkyl or hetero (C8 l2) polycycloaryl (C06) alkyl and R15 is hydrogen or (C16)alkyl, and wherein within R14 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,R16, X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4C(O)R16,X4C(O)OR16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4isabondor(C16)alkylene,R16ishydrogenorX4NR17C(NR17)NR16R17,wherein (C16) alkyl and R17 is (C312) cycloalkyl (CO6) alkyl, hetero (C312) cycloalkyl (CO6) alkyl, (C912)polycycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C8 l2) polycycloaryl (C06) alkyl, or (iii) a group selected from (C312)cycloalkyl(C06) alkyl, hetero (C3 l2) cycloalkyl (CO 6) alkyl, (C6 l2) aryl (C06) alkyl, andhetero(C512)aryl(C06)alkyl,(C912)polycycloaryl(C06)alkyl hetero (C8 l2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,R16, X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4C(O)R16,X4C(O)OR16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4NR17C(NR17)NR16R17, wherein X4, R16 and R"are as defined above; wherein within R9 and/or Rl° any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Calkyi, (Calkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X4NR12R12, XRNR12C(O)OR12, X4OR12,X4SR12,X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12, X4S(O)2NR12R12,X4P(O)(OR4)OR12,X4C(O)OR12,X4C(O)NR12R12, X4NR12C(O)R13,X4S(O)R13,X4S(O)2R13X4OP(O)(OR12)OR12,X4OC(O)R13, andX4C (o) Rl3, wherein X4, R12 and R13 are as defined above, or R9 taken together with R7 and/or R10 taken together with R8 form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene; and R"isXR18, wherein X5 isC (O),C (O) C (O)orS (O) 2, x6 is a bond,OorNRl9, wherein R19 is hydrogen or (C16)alkyl, and R18 is (i) (C110) alkyl optionally substituted by cyano, halo, nitro, NR12R12, NR12C(NR12)NR12R12,OR12,SR12,NR12C(O)OR12,NR12C(O)NR12R12, S(O)2NR12R12,P(O)(OR12)OR12,C(O)OR12,C(O)NR12R12, OP (O) (OR12)OR12,NR12C(0)R13,S(0)R13,S(0)2R13,C(0)R13,OR20,SR20, C(O)R20,C(O)OR20,C(O)NR20R21,NR20R21,S(O)R20,S(O)2R20, orNR21C(NR21)NR20R21,NR21C(O)R20,NR21C(O)OR20,NR21C(O)NR20R21 wherein R12 and R13 are as defined above, R20 is (C3 l2) cycloalkyl (C06) alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, (C9 l2) bicycloaryl (CO6) alkyl or hetero (C8 l2) bicycloaryl (C06) alkyl and R''at each occurrence independently is hydrogen or (Cl 6) alkyl, or (ii) hetero(C312)cycloalkyl(C06)alkyl, (C912)bicycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C812) bicycloaryl (Co6) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (Co6) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X4S(O)R22,X4S(O)2R22,X4C(O)R22,X4C(O)OR22,X4OR22,X4SR22, X4NR23C(O)R22,X4NR23C(O)OR22,X4C(O)NR22R23,X4NR22R23, X4NR23C(O)NR22R23 or X4NR23C(NR23)NR22R23, wherein X4 is as defined above, R22 is (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (CO6) alkyl or hetero (C56) aryl (CO6) alkyl and R23 at each occurrence independently is hydrogen or (Cl6) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (Ci. alkylidene, cyano, halo, halosubstituted (C14) alkyl, X4NR12C(O)OR12,X4NR12C(O)NR12R12,nitro,X4NR12R12, X4SR12,X4C(O)OR12,X4C(O)NR12R12,X4NR12C(NR12)NR12R12,X4OR12, X4OP(O)(OR3)OR12,X4OC(O)R13,X4S(O)2NR12R12,X4P(O)(OR3)OR12, X4S(O)2R13andX4C(O)R13,whereinX4,R13andX4NR12C(O)R13,X4S(O)R13, R13 are as defined above; R2 is hydrogen or (C16) alkyl or as defined below; R3 is hydrogen, (C16) alkyl or as defined below; and R4 is (i) hydrogen or (C16) alkyl, wherein said alkyl is optionally substituted with cyano, halo, NR12C(O)OR12,NR12C(O)NR12R12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, NR12C(O)R13,S(O)R13,S(O)2R13,C(O)R13,P(O)(OR12)OR12,OP(O)(OR12)OR12, <BR> <BR> S(O)R14,S(O)2R14,C(O)R14,C(O)OR14,OC(O)R14,NR14R15,OR14,SR14, <BR> C(O)NR14R15,S(O)2NR14R15,NR15C(O)NR14R15orNR15C(O)R14,NR15C(O)OR14, R12,R13,R14NR15C(NR15)NR14R15,wherein and asdefinedabove,or(ii)agroupare selected from (C312)cycloalkyl(C06)alkyl, hetero(C312)cycloalkyl(C06)alkyl, (C612)aryl(C06) alkyl, hetero (C512) aryl (CO6) alkyl, (C9 l2) polycycloaryl (CO6) alkyl and hetero (C8, 2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,X4C(O)R16,R16, X4NR16R17,X4NR17C(O)R16,X4NR17C(O)OR16,X4C(O)OR16,X4OC(O)R16, XCCQNRR17,XCCNRR17,X4NR17C(0)NR16R17orX4NR17C(NR17)NR16R17,<BR> <BR> <BR> <BR> <BR> wherein X4, R16 and R17 are as defined above; wherein within R9 and/or Rl° any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16)alkylidene, cyano, halo, halosubstituted (Calkyi, nitro, X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12,X4NR12R12,X4NR12C(O)OR12, X4C(O)OR12,X4C(O)NR12R12,X4S(O)2NR12R12,X4OR12,X4SR12, X4OC(O)R13,X4NR12C(O)R13,X4S(O)R13,X4P(O)(OR3)OR12,X4OP(O)(OR3)OR12, X4S (O) 2R13 andX4C (o) Rl3, wherein X4, R12 and R13 are as defined above, or R4 and R2 taken together form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene, or R4 and R3 together with the carbon atom to which both R4 and R3 are attached form (C38) cycloalkylene or (C38) heterocycloalkylene; or an Noxide derivative, prodrug derivative, individual isomer and mixtures of isomers; or a pharmaceutically acceptable salt thereof, but excluding compounds of the formula in which R3 and R4 are each hydrogen or (C16)alkyl, or together with the carbon atom to which they are both attached form (C3 s) cycloalkylene; RI is hydrogen or (C16)alkyl ; R9 is (C612)aryl(C16)alkyl, hetero (C512) aryl (Cl 6) alkyl, (C45) alkyl or cyclohexylmethyl; and R"is C (O) R18 wherein R18 is hetero (C312)cycloalkyl, (C612) aryl (CO6) alkyl or hetero (C5. i2) aryl (C0 6) alkyl.
34. The use of a compound of Formula (I): in which: Rl is a group of Formula (a) or (b): wherein: X2independentlyX1and are CH2S(O)2;or R5 and R6 are hydrogen or (Cl 6) alkyl; R7 and R8 are hydrogen or (C16) alkyl or as defined below; R9 and R'° independently are (i) (C16)alkyl optionally substituted with cyano, halo or nitro or (ii) a group selected from X3NR12R12, X3NR12C(O)OR12, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3C(O)OR12,X3P(O)(OR12)OR12,X3S(O)2NR12R12, X3S(O)R13,X3S(O)2R13,X3C(O)R13,X3OP(O)(OR12)OR12,X3NR12C(O)R13, X3OC(O)R14,X3NR15C(O)R14,X3NR15C(O)OR14,X3C(O)R14,X3C(O)OR14, X3NR15C(O)NR14R15,X3C(O)NR14R15,X3S(O)2NR14R15, X4S(O)R14,X4S(O)2R14,X4OR14,orX3NR15C(NR15)NR14R15,X4SR14 X3is(C16)alkylene,X4isabondor(C16)alkylene,R12ateachX4NR14R15,wherein occurrence independently is hydrogen, (C16)alkyl or halosubstituted (C13)alkyl, R13 is (Cl 6) alkyl or halosubstituted (C13) alkyl, R14 is (C3 l2) cycloalkyl (C06) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C612) aryl (Co. g) alkyl, hetero (C512) aryl (CO 6) alkyl, (C9 l2) polycycloaryl (C06) alkyl or hetero (C8 l2) polycycloaryl (C06) alkyl and R15 is hydrogen or (Calkyi, and wherein within R14 said cycloalkyi, heterocycloalkyi, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,R16, <BR> <BR> <BR> <BR> X4C(O)R16, X4C(O)OR16, X4OC(O)R16, X4NR16R17, X4NR17C(O)R16,<BR> X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4isabondor(C16)alkylene,R16ishydrogenorX4NR17C(NR17)NR16R17,wherein (C16) alkyl and Rl7 is (C3 l2) cycloalkyl (C06) alkyl, hetero (C312) cycloalkyl (CO6) alkyl, (C912)polycycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C8 l2) polycycloaryl (C06) alkyl, or (iii) a group selected from (C612)aryl(C06)alkyl,(C312)cycloalkyl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl, hetero (C512) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl and hetero (C8 l2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,R16, X4OC(O)R16,X4NR16R17,X4NR17C(O)R16,X4C(O)R16,X4C(O)OR16, X4S(O)2NR16R17,X4NR17C(O)NR16R17orX4NR17C(O)OR16,X4C(O)NR16R17, X4,R16andR17areasdefinedabove;whereinX4NR17C(NR17)NR16R17,wherein within R9 and/or R10 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X4NR12R12, X4NR12C(O)OR12, X4OR12,X4SR12,X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12, X4S(O)2NR12R12,X4P(O)(OR4)OR12,X4C(O)OR12,X4C(O)NR12R12, X4NR12C(O)R13,X4S(O)R13,X4S(O)2R13X4OP(O)(OR12)OR12,X4OC(O)R13, and X4C(O)R13, wherein X4, R12 and R13 are as defined above, or R9 taken together with R7 and/or Rl° taken together with R8 form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene; and R11 is X5X6R18, wherein X5 isC (O),C (O) C (O)orS (O) 2, x6 is a bond,OorNRl9, wherein R19 is hydrogen or (Cl 6) alkyl, and R18 is (i) (C110) alkyl optionally substituted by cyano, halo, nitro, NR12R12, NR12C(NR12)NR12R12,OR12,SR12,NR12C(O)OR12,NR12C(O)NR12R12, S(O)2NR12R12,P(O)(OR12)OR12,C(O)OR12,C(O)NR12R12, <BR> <BR> OPXOROR12,NRCCCQR13,S(0)R13,S(0)2R13,C(0)R13,OR20,SR20,<BR> <BR> S (O) R,S (0) 2R,C (O) R,C (O) OR,C (O) NR OR,NR OR, orNR21C(NR21)NR20R21,NR21C(O)R20,NR21C(O)OR20,NR21C(O)NR20R21 wherein R12 and R13 are as defined above, R20 is (C312)cycloalkyl(C06)alkyl, hetero(C512)aryl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,(C612)aryl(C06)alkyl, hetero(C812)bicycloaryl(C06)alkylandR21ateach(C912)bicycloaryl(C06)alkylor occurrence independently is hydrogen or (Cl 6) alkyl, or hetero(C312)cycloalkyl(C06)alkyl,(ii)(C312)cycloalkyl(C06)alkyl, (C912)bicycloaryl(C06)alkylor(C612)aryl(C06)alkyl,hetero(C512)aryl(C06)alkyl, hetero (C812) bicycloaryl (C06) alkyl or (iii) (C36) cycloalkyl (Co6) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X4S(O)R22,X4S(O)2R22,X4C(O)R22,X4C(O)OR22,X4OR22,X4SR22, X4NR23C(O)R22,X4NR23C(O)OR22,X4C(O)NR22R23,X4NR22R23, X4NR23C(NR23)NR22R23,X4NR23C(O)NR22R23or wherein X4 is as defined above, R22 is (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (Co. g) alkyl or hetero (C56) aryl (C06) alkyl and R23 at each occurrence independently is hydrogen or (CI6) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (C16) alkylidene, cyano, halo, halosubstituted (Cl 4) alkyl, X4NR12C(O)OR12,X4NR12C(O)NR12R12,nitro,X4NR12R12, X4SR12,X4C(O)OR12,X4C(O)NR12R12,X4NR12C(NR12)NR12R12,X4OR12, X4OP(O)(OR3)OR12,X4OC(O)R13,X4S(O)2NR12R12,X4P(O)(OR3)OR12, X4S(O)2R13andX4C(O)R13,whereinX4,R12andX4NR12C(O)R13,X4S(O)R13, R13 are as defined above; R2 is hydrogen or asdefinedbelow;or hydrogen,(C16)alkylorasdefinedbelow;andR3is (i)hydrogenor(C16)alkyl,whereinsaidalkylisoptionallysubstitutedwithR4is cyano, halo, NR12C(O)OR12,NR12C(O)NR12R12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, NR12C(O)R13,S(O)R13,S(O)2R13,C(O)R13,P(O)(OR12)OR12,OP(O)(OR12)OR12, S(O)R14,S(O)2R14,C(O)R14,C(O)OR14,OC(O)R14,NR14R15,OR14,SR14, C(O)NR14R15,S(O)2NR14R15,NR15C(O)NR14R15orNR15C(O)R14,NR15C(O)OR14, R12,R13,R14andR15areasdefinedabove,or(ii)agroupNR15C(NR15)NR14R15,wherein selected from (C312)cyclaolkyl(C06)alkyl, hetero(C312)cycloalkyl(C06)alkyl, (C612)aryl(C06)alkyl,and(C912)polycycloaryl(C06)alkyl saidcycloalkyl,heterocycloalkyl,aryl,hetero(C812)polycycloaryl(C06)alkyl,wherein heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X4OR16,X4SR16,X4S(O)R16,X4S(O)2R16,X4C(O)R16,R16, X4NR16R17,X4NR17C(O)R16,X4NR17C(O)OR16,X4C(O)OR16,X4OC(O)R16, X4NR17C(O)NR16R17orX4NR17C(NR17)NR16R17,X4C(O)NR16R17,X4S(O)2NR16R17, wherein X4, R16 and R17 are as defined above; wherein within R10and/or any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16)alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X4NR12C(O)NR12R12,X4NR12C(NR12)NR12R12,X4NR12R12,X4NR12C(O)OR12, X4C(O)OR12,X4C(O)NR12R12,X4S(O)2NR12R12,X4OR12,X4SR12, X4OC(O)R13,X4NR12C(O)R13,X4S(O)R13,X4P(O)(OR3)OR12,X4OP(O)(OR3)OR12, X4S(O)2R13 and X4,R12andR13areasdefinedabove,orwherein R4 and R2 taken together form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene, or R4 and R3 together with the carbon atom to which both R3areand attached form (C38)heterocycloalkylene;oranNoxidederivative,prodrug(C38)cycloalkyleneor derivative, individual isomer and mixtures of isomers; or a pharmaceutically acceptable salt thereof, but excluding compounds of the formula in which R3 and R4 are each hydrogen or (C16)alkyl, or together with the carbon atom to which they are both attached form (C3 s) cycloalkylene; Rs is hydrogen or (C16) alkyl; R9 is (C45)alkylorcyclohexylmethyl;andR11is(C612)aryl(C16)alkyl,hetero(C512)aryl(C16)alkyl, C (O) R18 wherein R18 is hetero (C3 l2) cycloalkyl, (C6 l2) aryl (C06) alkyl or hetero (C512) aryl (C0 6) alkyl, in the manufacture of a medicament for treating a disease in an animal in which cathepsin S activity contributes to the pathology and/or symptomatology of the disease.
35. A process for preparing a compound of Formula I: inwhich: R'is a group of Formula (a) or (b): wherein: X2independentlyX1and are CH2S(O)2;or R5 and R6 are hydrogen or (C16)alkyl ; R7 and R8 are hydrogen or (C16) alkyl or as defined below; R9 and R10 independently are (i) (C16)alkyl optionally substituted with cyano, halo, NR12C(O)OR12,NR12C(O)NR12R12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, NR12C(O)R13,S(O)R13,S(O)2R13,P(O)(OR12)OR12,OP(O)(OR12)OR12, <BR> <BR> C(0)R13,OR14,SR14,S(0)R14,SR14,C(0)R14,C(0)OR14,OC(0)R14,<BR> <BR> NRR15,NRCCCQR14,NRCXCQOR14,CNR'15,SNRR15, NR15C(O)NR14R15 or NR15C(NR15)NR14R15, wherein R12 at each occurrence independently is hydrogen, halosubstituted(C13)alkyl,R13is(C16)alkylor or halosubstituted (C13) alkyl, R14 is (C3 l2) cycloalkyl (C06) alkyl, hetero (C3 l2) cycloalkyl (CO 6) alkyl, (C6 l2) aryl (C06) alkyl, hetero (C512) aryl (C06) alkyl, (C912) polycycloaryl (CO6) alkyl or hetero (C8 l2) polycycloaryl (C06) alkyl and Rl5 is hydrogen or (C16) alkyl, and wherein within R14 said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3C(O)R16, X3C(O)OR16, X3OC(O)R16, X3NR16R17, X3NR17C(O)R16, X3NR17C(O)OR16, X3C(O)NR16R17, X3S(O)2NR16R17, X3NR17C(O)NR16R17 or X3isabondor(C16)alkylene,R16ishydrogenorX3NR17C(NR17)NR16R17,wherein (Cl 6) alkyl and Rl7 is (C3 l2) cycloalkyl (C06) alkyl, hetero (C3, 2) cycloalkyl (CO6) alkyl, (C612)aryl(C06)alkyl, or(C912)polycycloaryl(C06)alkyl hetero (C8 l2) polycycloaryl (C06) alkyl, or (ii) a group selected from (C612)aryl(C06)alkyl,(C312)cycloalkyl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl, andhetero(C512)aryl(C06)alkyl,(C912)polycycloaryl(C06)alkyl hetero (C812)polycycloaryl(C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,R16, X3OC(O)R16,X3NR16R17,X3NR17C(O)R16,X3C(O)R16,X3C(O)OR16, X3S(O)2NR16R17,X3NR17C(O)NR16R17orX3NR17C(O)OR16,X3N(O)NR16R17, X3NR17C(NR17)NR16R17, wherein X3, R16 and R17 are as defined above; wherein within R9 and/or R10 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16)alkyl, (C16) alkylidene, cyano, halo, halosubstituted (C14)alkyl, nitro, X3NR12R12, X3NR12C(O)OR12, X3OR12,X3SR12,X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12, X3S(O)2NR12R12,X3P(O)(OR3)OR12,X3C(O)OR12,X3C(O)NR12R12, X3NR12C(O)R13,X3S(O)R13,X3S(O)2R13X3OP(O)(OR3)OR12,X3OC(O)R13, andandX3C(O)R13, wherein X3, R13and are as defined above, or R9 taken together with R7 and/or Rl° taken together with R8 form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene; and X4X5R18,whereinX4isC(O),C(O)C(O)orS(O)2,X5isaR11is bond,OorNRl9, wherein R19 is hydrogen or (C16)alkyl, and R18 is (i) (C110) alkyl optionally substituted by cyano, halo, nitro, NR12R12, NR12C(NR12)NR12R12,OR12,SR12,NR12C(O)OR12,NR12C(O)NR12R12, S(O)2NR12R12,P(O)(OR12)OR12,C(O)OR12,C(O)NR12R12, S(O)R13,S(O)2R13,C(O)R13,OR20,SR20,OP(O)(OR12)OR12,NR12C(O)R13, S (O) R20,S (O)2R20, C(O)R20, C(O)OR20, C(O)NR20R21, NR20R21, orNR21C(NR21)NR20R21,NR21C(O)R20,NR21C(O)OR20,NR21C(O)NR20R21 wherein R12 and R13 are as defined above, R20 is (C312) cycloalkyl (CO6) alkyl, hetero (C312)cycloalkyl(C06) alkyl, (C6 l2) aryl (Co. 6) alkyl, hetero (C512) aryl (Co6) alkyl, (C912) l2) bicycloaryl (C06) alkyl or hetero (C8 l2) bicycloaryl (CO6) alkyl and R21 at each occurrence independently is hydrogen or (C16) alkyl, or hetero(C312)cycloalkyl(C06)alkyl,(ii)(C312)cycloalkyl(C06)alkyl, (C612)aryl(C06) alkyl, hetero (C512) aryl (CO6) alkyl, (C912) bicycloaryl (CO6) alkyl or hetero (C812) bicycloaryl (C06) alkyl or (iii) (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (C06) alkyl or hetero (C56) aryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, phenyl or heteroaryl is substituted by X3S(O)R22,X3S(O)2R22,X3C(O)R22,X3C(O)OR22,X3OR22,X3SR22, X3NR23C(O)R22,X3NR23C(O)OR22,X3C(O)NR22R23,X3NR22R23, X3NR23C(O)NR22R23 or X3NR23C(NR23)NR22R23, wherein X3 is as defined above, R22 is (C36) cycloalkyl (C06) alkyl, hetero (C36) cycloalkyl (C06) alkyl, phenyl (CO6) alkyl or hetero (C56) aryl (CO6) alkyl and R23 at each occurrence independently is hydrogen or (Cl 6) alkyl; wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C16) alkyl, (C16)alkylidene, cyano, halo, halosubstituted (Cl 4) alkyl, X3NR12C(O)OR12,X3NR12C(O)NR12R12,nitro,X3NR12R12, X3NR12C(NR12)NR12R12,X3C(O)OR12,X3C(O)NR12R12,X3SR12, X3S(O)2NR12R12,X3OC(O)R13,X3OP(O)(OR3)OR12, NRCR13,X3S(0)R13,XCCR13andX3C(0)R13,whereinX3,R12and R13 are as defined above; R2 is hydrogen or (Cl6) alkyl or as defined below; R3 is hydrogen, (C16)alkyl or as defined below; and R4 is (i) hydrogen or (C16)alkyl, wherein said alkyl is optionally substituted with cyano, halo, NR12C(O)OR12,NR12C(O)NR12R12,NR12R12, SR12,C(O)OR12,C(O)NR12R12,S(O)2NR12R12,NR12C(NR12)NR12R12,OR12, <BR> <BR> PCOXOROR12,OPCOXOR'OR12,NRCR13,S(0)R13,S(0)2R13,C(0)R13,<BR> <BR> OR14,SR14,S(0)R14,S(0)2R14,C(0)R14,C(0)OR14,OC(0)R14,NR'15,<BR> <BR> NR'5C(0)R14,NRCCOOR14,CNRR15,S(0)2NR14R15,NRCNRR15or R12,R13,R14andR15areasdefinedabove,or(ii)agroupNR15C(NR15)NR14R15,wherein (C312)cycloalkyl(C06)alkyl,hetero(C312)cycloalkyl(C06)alkyl,selectedfrom (C612)aryl(C06) alkyl, hetero (Cs l2) aryl (CO6) alkyl, (C912)polycycloaryl(C06) alkyl and hetero (C8 l2) polycycloaryl (C06) alkyl, wherein said cycloalkyl, heterocycloalkyl, aryl, heteroaryl, polycycloaryl or heterpolycycloaryl ring optionally is substituted by a group selected X3OR16,X3SR16,X3S(O)R16,X3S(O)2R16,X3C(O)R16,R16, X3NR16R17,X3NR17C(O)R16,X3NR17C(O)OR16,X3C(O)OR16,X3OC(O)R16, X3NR17C(O)NR16R17orX3NR17C(NR17)NR16R17,X3C(O)NR16R17,X3S(O)2NR16R17, wherein X3, R16 and R17 are as defined above; wherein within R9 and/or R10 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (Cl 6) alkyl, (Ci. alkylidene, cyano, halo, halosubstituted (Calkyi, nitro, X3NR12C(O)NR12R12,X3NR12C(NR12)NR12R12,X3NR12R12,X3NR12C(O)OR12, X3C(O)OR12,X3C(O)NR12R12,X3S(O)2NR12R12,X3OR12,X3SR12, X3OC(O)R13,X3NR12C(O)R13,X3S(O)R13,X3P(O)(OR3)OR12,X3OP(O)(OR3)OR12, X3S (O) 2Rl3 andX3C (o) Rl3, wherein X3, R12 and R13 are as defined above, or R4 and R2 taken together form trimethylene, tetramethylene or phenylene1,2dimethylene, optionally substituted with hydroxy, oxo or methylene, or R4 and R3 together with the carbon atom to which both R4 and R3 are attached form (C38) cycloalkylene or (C38) heterocycloalkylene; and the Noxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers; and the pharmaceutically acceptable salts thereof; which process comprises: (A) reacting a compound of Formula 2: or a protected derivative thereof, with a compound of the formula R'OY, or a protected derivative thereof, in which Y is hydrogen or 2,5dioxopyrrolidin1yl and each R', R2, R3 and R4 are as defined above; or (B) reacting a compound of Formula 3: or a protected derivative thereof, with ammonia to provide a corresponding amide and then reacting the amide with trifluoroacetic anhydride, in which each R', R2, R3 and R4 are as defined above; (C) optionally deprotecting a protected derivative of a compound of Formula I to provide a corresponding unprotected derivative; (D) optionally converting a compound of Formula I into a pharmaceutically acceptable salt; (E) optionally converting a salt form of a compound of Formula I to nonsalt form; (F) optionally converting an unoxidized form of a compound of Formula I into a pharmaceutically acceptable Noxide; (G) optionally converting an Noxide form of a compound of Formula I its unoxidized form; (H) optionally converting a nonderivatized compound of Formula I into a pharmaceutically prodrug derivative; and (I) optionally converting a prodrug derivative of a compound of Formula I to its nonderivatized form.
Description:
INTERNATIONAL SEARCH REPORT tinter..-, ional Application No PCT/US00/06747 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X DATABASE CHEMABS [Online] 1-3, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, 14-23 OHIO,US; YOSHIDA, HIROSHI ET AL :"Preparation of N- (2-chloroisonicotinoyl) amino acid amides as agrochemical microbicides" retrieved from STN Database accession no. 110: 213341 XP002144654 abstract &JP 63 301868 A (NIPPON KAYAKU CO., LTD., JAPAN) 8 December 1988 (1988-12-08) X DATABASE CHEMABS [Online] 1-3, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, 14-23 OHIO,US ; SUZUE, SEIGO ET AL :"Hepatic agents. I. Synthesis of aminoacyl (and hydroxyacyl)aminoacetonitriles" retrieved from STN Database accession no. 70 : 11969 XP002144655 abstract &CHEM. PHARM. BULL. (TOKYO) (1968), 16 (8), 1417-32, X WO 98 01133 A (AIBE KAZUHIKO; NOSHIRO 1-3, OSAMU (JP); IGARASHI SUSUMU (JP); ISHII 14-23 YAS) 15 January 1998 (1998-01-15) page 79 P, X WO 99 24460 A (NOVARTIS ERFINDUNGEN 1-35 VERWALTUN ; ALTMANN EVA (CH); LATTMANN RENE (C) 20 May 1999 (1999-05-20) examples 1-419 2 international application No. INTERNATIONAL SEARCH REPORT PCT/US 00/06747 Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This International Search Report has not been established in respect of certain claims under Article 17 (2) (a) for the following reasons: 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 9-12,33 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. 2. Claims Nos. : 1-12,14-35 (partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically : see FURTHER INFORMATION sheet PCT/ISA/210 3. jj Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4 (a). Box 11 Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet 1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. 2. jj As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12,14-35 (all partially) Remark on Protest The additional search fees were accompanied by the applicant's protest. u j No protest accompanied the payment of additional search fees. u FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 This International Searching Authority found multiple (groups of) inventions in this international application, as follows: 1. Claims: 1-12,14-35 (all partially) Compounds of formula I, wherein X1=C (0), R4=H and R3=H or R4=H and R3= (Cl-6) Alkyl or R4=C (1-6) Alkyl. 2. Claims: 1-12,14-35 (all partially) Compounds of formula I, wherein X1=C (0), R4 is selected from subgroup (ii) and represents a functional group comprising a (poly) cyloalkyl or (poly) cycloaryl moiety. 3. Claims: 1-12,14-35 (all partially) A compound of formula I wherein X1=C (0) and R4 taken together with R2 or R3 forms a cyclic structure. 4. Claims: 1-12,14-35 (all partially) ; 13 A compound of formula I wherein X1=CH2S (0) 2. FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 Continuation of Box 1. 2 Claims Nos.: 1-12,14-35 (partially) Present claims 1-35 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables and possible permutations that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim (s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons it appears impossible to execute a meaningful search and/or issue a complete search report over the whole breadth of the above mentioned claim (s). Consequently, the search and the report can only be considered complete for: First subject (see suppl. sheet B): Compounds as defined in the first invention, according to formula 1 comprising a moiety R9 as defined by claim 4. The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. INTERNATIONAL SEARCH REPORT Inter,.-. ional Application No Informationonpatent familymembers PCT/US /06747 Patent document Publication Patent family Publication cited in search report date member (s) date JP 63301868 A 08-12-1988 NONE WO 9801133 A 15-01-1998 AU 3359697 A 02-02-1998 WO 9924460 A 20-05-1999 AU 1487399 A 31-05-1999 BR 9813197 A 29-08-2000 EP 1028942 A 23-08-2000 NO 20002320 A 04-07-2000 ZA 9810073 A 05-05-1999 JP 42009133 B NONE